Improving Opioid Use Disorder Risk Modelling through Behavioral and Genetic Feature Integration

TL;DR

This study introduces a novel computational framework that combines behavioral mobility data and genetic information to improve the prediction of opioid use disorder risk, potentially aiding personalized treatment strategies.

Contribution

It develops algorithms to synthesize and integrate mobility and genetic data for enhanced OUD risk modeling, addressing data availability challenges.

Findings

Integration improves classification metrics for OUD risk

Mobility features have greater influence on risk prediction

Genetic data significantly contribute in linear models

Abstract

Opioids are an effective analgesic for acute and chronic pain, but also carry a considerable risk of addiction leading to millions of opioid use disorder (OUD) cases and tens of thousands of premature deaths in the United States yearly. Estimating OUD risk prior to prescription could improve the efficacy of treatment regimens, monitoring programs, and intervention strategies, but risk estimation is typically based on self-reported data or questionnaires. We develop an experimental design and computational methods that combine genetic variants associated with OUD with behavioral features extracted from GPS and Wi-Fi spatiotemporal coordinates to assess OUD risk. Since both OUD mobility and genetic data do not exist for the same cohort, we develop algorithms to (1) generate mobility features from empirical distributions and (2) synthesize mobility and genetic samples assuming an expected level of disease co-occurrence. We show that integrating genetic and mobility modalities improves risk modelling using classification accuracy, area under the precision-recall and receiver operator characteristic curves, and $F_1$ score. Interpreting the fitted models suggests that mobility features have more influence on OUD risk, although the genetic contribution was significant, particularly in linear models. While there exist concerns with respect to privacy, security, bias, and generalizability that must be evaluated in clinical trials before being implemented in practice, our framework provides preliminary evidence that behavioral and genetic features may improve OUD risk estimation to assist with personalized clinical decision-making.